1. Home
  2. MLYS vs AMC Comparison

MLYS vs AMC Comparison

Compare MLYS & AMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$25.85

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo AMC Entertainment Holdings Inc.

AMC

AMC Entertainment Holdings Inc.

HOLD

Current Price

$3.30

Market Cap

2.4B

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
AMC
Founded
2019
1920
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Movies/Entertainment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.4B
IPO Year
2023
2007

Fundamental Metrics

Financial Performance
Metric
MLYS
AMC
Price
$25.85
$3.30
Analyst Decision
Strong Buy
Hold
Analyst Count
7
4
Target Price
★ $48.67
$2.03
AVG Volume (30 Days)
1.2M
★ 21.8M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 37.43
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $4,848,900,000.00
Revenue This Year
N/A
$11.41
Revenue Next Year
N/A
$5.18
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 4.57
52 Week Low
$22.30
$0.93
52 Week High
$47.65
$3.18

Technical Indicators

Market Signals
Indicator
MLYS
AMC
Relative Strength Index (RSI) 39.48 74.04
Support Level $22.36 $2.34
Resistance Level $31.36 N/A
Average True Range (ATR) 1.48 0.17
MACD -0.40 0.06
Stochastic Oscillator 5.09 98.47

Price Performance

Historical Comparison
MLYS
AMC

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About AMC AMC Entertainment Holdings Inc.

AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.

Share on Social Networks: